| Unadjusted | Adjusted | ||||
---|---|---|---|---|---|---|
 | β (95%CI) | p-value | R2 | β (95%CI) | p-value | R2 |
All studies (n=1,132) | ||||||
 DAS28-ESR | 10.71 (10.0, 11.4) | <0.001 | 0.423 | 11.5 (10.7, 12.2) | <0.001 | 0.534 |
 Patient global | 0.89 (0.86, 0.92) | <0.001 | 0.774 | 0.86 (0.83, 0.89) | <0.001 | 0.793 |
 Tender joint counts | 2.41 (2.20, 2.61) | <0.001 | 0.319 | 2.20 (1.98, 2.42) | <0.001 | 0.410 |
 Swollen joint counts | 2.02 (1.78, 2.27) | <0.001 | 0.188 | 1.99 (1.73, 2.25) | <0.001 | 0.325 |
 ESR | 0.15 (0.06, 0.23) | <0.001 | 0.011 | 0.20 (0.11, 0.29) | <0.001 | 0.197 |
Early active RA trials (n = 490) | ||||||
 DAS28-ESR | 11.26 (10.21, 12.31) | <0.001 | 0.477 | 10.61 (9.52, 11.71) | <0.001 | 0.539 |
 Patient global | 0.86 (0.81, 0.90) | <0.001 | 0.737 | 0.82 (0.77, 0.87) | <0.001 | 0.759 |
 Tender joint counts | 2.08 (1.78, 2.38) | <0.001 | 0.277 | 1.72 (1.42, 2.03) | <0.001 | 0.382 |
 Swollen joint counts | 2.05 (1.78, 2.32) | <0.001 | 0.313 | 1.88 (1.61, 2.16) | <0.001 | 0.412 |
 ESR | 0.12 (0.01, 0.24) | 0.033 | 0.009 | 0.14 (0.03, 0.25) | 0.016 | 0.205 |
Established active RA trials (n=469) | ||||||
 DAS28-ESR | 12.41 (11.13, 13.68) | <0.001 | 0.439 | 12.62 (11.35, 13.89) | <0.001 | 0.507 |
 Patient global | 0.91 (0.87, 0.96) | <0.001 | 0.795 | 0.89 (0.84, 0.93) | <0.001 | 0.801 |
 Tender joint counts | 2.75 (2.44, 3.06) | <0.001 | 0.391 | 2.65 (2.33, 2.98) | <0.001 | 0.426 |
 Swollen joint counts | 2.77 (2.16, 3.39) | <0.001 | 0.143 | 2.64 (1.99, 3.28) | <0.001 | 0.214 |
 ESR | 0.12 (−0.01, 0.26) | 0.077 | 0.007 | - | - | - |
Remission/LDA studies (n=173) | ||||||
 DAS28-ESR | 10.51 (8.02, 12.99) | <0.001 | 0.289 | 10.02 (6.93, 13.11) | <0.001 | 0.481 |
 Patient global | 0.94 (0.87, 1.01) | <0.001 | 0.792 | 0.91 (0.82, 1.00) | <0.001 | 0.859 |
 Tender joint counts | 3.00 (1.84, 4.16) | <0.001 | 0.132 | 2.40 (1.28, 3.52) | <0.001 | 0.381 |
 Swollen joint counts | 0.70 (−0.83, 2.24) | 0.368 | 0.005 | - | - | - |
 ESR | 0.19 (−0.10, 0.48) | 0.201 | 0.010 | - | - | - |